Tech Company Financing Transactions
Emendo Biotherapeutics Funding Round
On 1/17/2020, Emendo Biotherapeutics received $61 million in Series B investment from Anges Quebec and private investors.
Transaction Overview
Company Name
Announced On
1/17/2020
Transaction Type
Venture Equity
Amount
$61,000,000
Round
Series B
Investors
Anges Quebec (Lead Investor)
Proceeds Purpose
This financing provides a strong foundation from which we can accelerate our proprietary OMNI gene editing platform towards a broad clinical pipeline for addressing devastating untreatable diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 W 61st St.
New York, NY 10069
USA
New York, NY 10069
USA
Phone
Website
Email Address
Overview
Emendo Biotherapeutics is a pioneering, next generation CRISPR company. Our unique approach allows us to make any gene targetable, transforming the current landscape of genetic medicine.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Baram
Chief Medical Officer
Todd Wider
Executive Vice President
Rachel Diamant
VP - R & D
Asael Herman
Browse more venture capital transactions:
Prev: 1/17/2020: NextNav Holdings venture capital transaction
Next: 1/17/2020: Loliware venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs